This post is not from the Reed Smith or Dechert sides of the blog.

We previously posted about the Delaware Supreme Court’s ruling that proper application of Delaware Rule 702 required the exclusion of plaintiffs’ general causation experts in the Zantac litigation. Since then, we’ve been waiting for the other shoe to drop.  Last week, it dropped with a resounding boom. Today’s decision applied the Delaware Supreme Court’s ruling and dismissed over 80,000 cases. In re Zantac (Ranitidine) Litig., No. N22C-090101, 2026 WL 1009008 (Del. Super. Apr. 14, 2026).

The decision focuses on the question of which plaintiffs are bound by the exclusion of the plaintiffs’ general causation experts. The court denied plaintiffs leave to supplement their expert reports on December 1, 2025, and the defense argued that all plaintiffs with cases filed before December 1, 2025, are bound by the ruling. Recognizing that the litigation was about to be eviscerated, plaintiffs made a number of desperate arguments.